Biofrontera reports record FY 2024 revenue $37.3M, up 9.5% YoY; Q4 net loss $1.4M

Biofrontera Inc.

Record total revenues $37.3M for 2024, +9.5% from $34.1M in 2023; Q4 revenues $12.6M, +18.5% YoY.
Q4 2024 net loss $1.4M ($0.19/share) vs net income $3.5M ($1.65/share) in Q4 2023 due to prior-year legal settlement gain.
Cash and equivalents $5.9M at Dec 31, 2024 vs $1.3M at Dec 31, 2023; Ameluz transfer price reduced from 50% to 25% through 2025.
Placed 100 RhodoLED XL lamps since June 2024 launch; FDA approved up to 3 tubes of Ameluz per treatment.
Phase 3 Study for Ameluz-PDT in superficial BCC achieved statistically significant results; initiated Phase 1 PK study for AK.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.